Dependence on Sales of TAMAGOSAMIN
First written in FY2019. 3 of 5 entries say "Softened", first in FY2022. Latest entry: FY2024.
Pharma Foods International moved to the "Worse" side of this theme in 2021, 2 years before the typical company in this theme (2023).
The whole theme swung hardest in 2024: 13 of 48 companies on the "Worse" side.
4 other companies' latest entry also says "Softened".
- FY2024SoftenedAnnual report
「Sales of “Newmo hair-growth lotion,” the group’s core product, accounted for 33.9% of group sales in the fiscal year ended July 2024.」
Reliance on Newmo hair-growth lotion sales continued, although the ratio declined from 38.2% in the previous fiscal year to 33.9%. - FY2023SoftenedAnnual report
「Sales of “Newmo hair-growth lotion,” the group’s core product, accounted for 38.2% of group sales in the fiscal year ended July 2023.」
Reliance on Newmo hair-growth lotion sales continued, although the ratio declined from 46.5% in the previous fiscal year to 38.2%. - FY2022SoftenedAnnual report
「Sales of “Newmo® hair-growth lotion,” the group’s core product, accounted for 46.5% of group sales in the fiscal year ended July 2022.」
Reliance on Newmo sales continued, although the ratio declined from 57.2% in the previous disclosure to 46.5%. - FY2021ReframedAnnual report
「Sales of “Newmo® hair-growth lotion,” the group’s core product, accounted for 57.2% of group sales in the fiscal year ended July 2021.」
Reliance on a single product shifted from the former core product, Tamasamin, to Newmo hair-growth lotion, whose sales accounted for 57.2% of consolidated sales, according to the disclosure. - FY2019First statedAnnual report
「Sales of “Tamasamin®,” the group’s core product, accounted for 42.9% of group sales in the fiscal year ended July 2019.」
Sales of the core product Tamasamin accounted for 42.9% of consolidated sales, indicating that unforeseen circumstances in procurement or sales could affect performance.